Clinical trial · Observational
Care Pathway and Associated Costs of Patients Treated With CAR T-cells Based on SNDS Data
NCT06392763CI-TRIAL-00076604completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective cohort study, based on the French medico-administrative database (SNDS), evaluated the care pathway, the effectiveness of management and the costs associated with patients treated with chimeric antigen receptor (CAR) T cells (CART-cells) (KYMRIAH or YESCARTA): paediatric and young adult patients (up to and including 25 years of age) with acute lymphoblastic leukaemia (ALL); and adult patients (18 years of age or older) with DLBCL.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia (ALL) | Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
| Diffuse Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (4)
- label
- KYMRIAH DLBCL
- label
- YESCARTA DLBCL
- label
- CAR-T DLBCL
- label
- KYMRIAH ALL
Primary outcomes (12)
- measure
- Number of medicine, surgery, obstetrics and odontology (MCO) stays per patient
- timeFrame
- Up to 36 months
- measure
- Number of outpatient visit (ACE) stays per patient
- timeFrame
- Up to 36 months
- measure
- Number of emergency room visits not followed by hospitalisation per patient
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
Show eligibility criteria text
Inclusion criteria: DLBCL population: * Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND * Diagnosed with DLBCL (International Classification of Diseases \[ICD-10 C833\]) when receiving CAR-T AND * Being 18 years of age or older. ALL population: * Patients with hospitalisation for CAR T-cell administration from 2017 to 2020 AND * Diagnosed with ALL (ICD-10 C910) when receiving CAR-T AND * Being 25 years of age or younger. Exclusion criteria: DLBCL population: • Patients hospitalised with a diagnosis other than DLBCL during the historical period or during the index stay. ALL population: • Patients hospitalised with a diagnosis other than ALL during the historical period or during the index stay.
References
Publications (0)
Data not yet available
No reference posted for this study.